Group II/group III metabotropic glutamate receptor antagonist, showing selectivity for group II in electrophysiological studies.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in 1eq. NaOH|
Preparing Stock Solutions
The following data is based on the product molecular weight 233.23. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.29 mL||21.44 mL||42.88 mL|
|5 mM||0.86 mL||4.29 mL||8.58 mL|
|10 mM||0.43 mL||2.14 mL||4.29 mL|
|50 mM||0.09 mL||0.43 mL||0.86 mL|
References are publications that support the products' biological activity.
Bedingfield et al (1996) Novel potent selective phenylglycine antagonists of metabotropic glutamate receptors. Eur.J.Pharmacol. 309 71 PMID: 8864696
Bushell et al (1996) Pharmacological antagonism of the actions of group II and group III mGluR agonists in the lateral perforant path of rat hippocampal slices. Br.J.Pharmacol. 117 1457 PMID: 8730739
Jane et al (1995) New phenylglycine derivatives with potent and selective antagonist activity at presynaptic glutamate receptors in neonatal rat spinal cord. Neuropharmacology 34 851 PMID: 8532166
If you know of a relevant reference for MTPG, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: MTPG, supplier, Group, II, group, III, mGlur, antagonists, selective, Receptors, mGlu2, mGlu3, mGluR3, mGluR2, Glutamate, Metabotropic, Glutamate, (Metabotropic), Group, II, Receptors, Glutamate, (Metabotropic), Group, II, Receptors, Tocris Bioscience
Citations for MTPG
Citations are publications that use Tocris products.
Currently there are no citations for MTPG. Do you know of a great paper that uses MTPG from Tocris? If so please let us know.
Reviews for MTPG
There are currently no reviews for this product. Be the first to review MTPG and earn rewards!
Have you used MTPG?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.